Literature DB >> 9816316

Endogenous interleukin 6 can function as an in vivo growth- stimulatory factor for advanced-stage human melanoma cells.

C Lu1, C Sheehan, J W Rak, C A Chambers, N Hozumi, R S Kerbel.   

Abstract

We have previously shown that a majority of human melanoma cell lines derived from early-stage lesions were growth inhibited by exogenous interleukin 6 (IL-6) in vitro, whereas cell lines from advanced-stage lesions were resistant to such IL-6-induced growth inhibition. Among the resistant melanoma cell lines, 50-60% constitutively produced IL-6, which appeared to function as a growth stimulator in vitro, based on the growth-suppressive effects of antisense oligonucleotides to the IL-6 gene. The present study was primarily aimed at evaluating whether endogenous IL-6 also functions in vivo as a growth modulator for IL-6-producing and -nonproducing melanoma cells. To do so, we first introduced an IL-6 expression vector into IL-6-nonproducing human melanoma cells using WM35, an early-stage (radial growth phase) cell line, the growth of which is normally inhibited by IL-6, and WM983A, an advanced-stage cell line, the growth of which in vitro is not affected by exogenous IL-6. None of the IL-6-producing transfectants showed a significant alteration in tumor growth in nude mice. Next, two IL-6-producing melanoma cell lines, both of which were derived from metastases, MeWo and WM9, and which are growth resistant to exogenously added IL-6, were transfected with an antisense IL-6 expression vector. Several transfectant clones manifested a constitutive decrease in IL-6 gene expression and protein production, and they also gave rise to much smaller tumors with slower growth rates and longer latency periods. However, these IL-6 antisense transfectants were not growth suppressed in in vitro cell cultures, relative to their respective parental controls. Taken together, the results demonstrate that endogenous IL-6 can indeed function as a growth stimulator for human cutaneous melanomas in vivo. This growth-stimulatory or survival mechanism remains to be clarified but may be paracrine rather than autocrine in nature.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816316

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  10 in total

Review 1.  The essence of senescence.

Authors:  Thomas Kuilman; Chrysiis Michaloglou; Wolter J Mooi; Daniel S Peeper
Journal:  Genes Dev       Date:  2010-11-15       Impact factor: 11.361

2.  GLI2 transcription factor mediates cytokine cross-talk in the tumor microenvironment.

Authors:  Sherine F Elsawa; Luciana L Almada; Steven C Ziesmer; Anne J Novak; Thomas E Witzig; Stephen M Ansell; Martin E Fernandez-Zapico
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

3.  Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

Authors:  A M Petit; J Rak; M C Hung; P Rockwell; N Goldstein; B Fendly; R S Kerbel
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

4.  Interleukin-6-producing cells in a human glioblastoma cell line are not affected by ionizing radiation.

Authors:  Jean-Jacques Dubost; Christine Rolhion; Andrei Tchirkov; Suzanne Bertrand; Jacques Chassagne; Annie Dosgilbert; Pierre Verrelle
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

5.  The calcium-binding protein S100B reduces IL6 production in malignant melanoma via inhibition of RSK cellular signaling.

Authors:  Milad J Alasady; Alexander R Terry; Adam D Pierce; Michael C Cavalier; Catherine S Blaha; Kaylin A Adipietro; Paul T Wilder; David J Weber; Nissim Hay
Journal:  PLoS One       Date:  2021-08-19       Impact factor: 3.240

Review 6.  Senescence-messaging secretome: SMS-ing cellular stress.

Authors:  Thomas Kuilman; Daniel S Peeper
Journal:  Nat Rev Cancer       Date:  2009-01-09       Impact factor: 60.716

7.  Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway.

Authors:  Hannes Steiner; Sonia Godoy-Tundidor; Hermann Rogatsch; Andreas P Berger; Dietmar Fuchs; Barbara Comuzzi; Georg Bartsch; Alfred Hobisch; Zoran Culig
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

8.  The -174 G/C polymorphism in interleukin-6 (IL-6) promoter region is associated with serum IL-6 and carcinoembryonic antigen levels in patients with colorectal cancers in Taiwan.

Authors:  Kun-Yun Yeh; Ying-Ying Li; Ling-Ling Hsieh; Jim-Ray Chen; Rei-Ping Tang
Journal:  J Clin Immunol       Date:  2009-08-29       Impact factor: 8.317

9.  Proinflammatory and Anti-Inflammatory Cytokines Mediated by NF-κB Factor as Prognostic Markers in Mammary Tumors.

Authors:  Gustavo Rodrigues Martins; Gabriela Bottaro Gelaleti; Marina Gobbe Moschetta; Larissa Bazela Maschio-Signorini; Debora Ap Pires de Campos Zuccari
Journal:  Mediators Inflamm       Date:  2016-02-16       Impact factor: 4.711

10.  Differential baseline and response profile to IFN-gamma gene transduction of IL-6/IL-6 receptor-alpha secretion discriminate primary tumors versus bone marrow metastases of nasopharyngeal carcinomas in culture.

Authors:  Andy Shau-Bin Chou; Hsin-Yi Wang; Hung-Chang Chen; Ming-Hsiu Tsai; Cheng-Keng Chuang; Shuen-Kuei Liao
Journal:  BMC Cancer       Date:  2009-06-05       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.